354764-98-0

Basic information

• Product Name: S-(-)-methyl 2-α-[N-t-butoxycarbonyl]amino-β-phenylpropionyl-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-3-carboxylate
• Synonyms: S-(-)-methyl 2-α-[N-t-butoxycarbonyl]amino-β-phenylpropionyl-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-3-carboxylate
• CAS NO: 354764-98-0
• Molecular Weight: 477.56
• Mol File: 354764-98-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: S-(-)-methyl 2-α-[N-t-butoxycarbonyl]amino-β-phenylpropionyl-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: S-(-)-methyl 2-α-[N-t-butoxycarbonyl]amino-β-phenylpropionyl-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-3-carboxylate(354764-98-0)
• EPA Substance Registry System: S-(-)-methyl 2-α-[N-t-butoxycarbonyl]amino-β-phenylpropionyl-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-3-carboxylate(354764-98-0)

Safety Data

• Hazardous Substances Data: 354764-98-0(Hazardous Substances Data)

Upstream product

• 4299-70-1 L-tryptophan methyl ester 
• 7524-52-9 (S)-tryptophan methyl ester hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 63-91-2 L-phenylalanine 
• 42438-90-4 3-carboxy-1,2,3,4-tetrahydro-2-carboline 
• 73-22-3 L-Tryptophan 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 79815-18-2 methyl (3S)-1,2,3,4-tetrahydro-β-carboline-3-carboxylate 

Relevant articles and documents

Exploration of TRPM8 Binding Sites by β-Carboline-Based Antagonists and Their in Vitro Characterization and in Vivo Analgesic Activities

Transient receptor potential melastatin 8 (TRPM8) ion channel represents a valuable pharmacological option for several therapeutic areas. Here, a series of conformationally restricted derivatives of the previously described TRPM8 antagonist N,N′-dibenzyl

Toward breast cancer resistance protein (BCRP) inhibitors: design, synthesis of a series of new simplified fumitremorgin C analogues

In this study, we report the design and synthesis of a series of new simplified fumitremorgin C analogues. The preliminary biological study indicated some of these simplified fumitremorgin C might be developed into breast cancer resistance inhibitors.